M. Zouhair Atassi

M. Zouhair Atassi

Auto-generated profile, based on publicly available information

M. Zouhair Atassi

Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Immunobiology
Verified
Journal Article
Closed access
MAM. Zouhair Atassi
M. Zouhair Atassi
BDBehzod Z. Dolimbek
Behzod Z. Dolimbek
JJJoseph Jankovic
Joseph Jankovic
LSLance E. Steward
Lance E. Steward
KAK. Roger Aoki
K. Roger Aoki

25 November 2010 in International Journal of Immunogenetics
Verified
Journal Article
Closed access
PDF file
PDP. R. Deitiker
P. R. Deitiker
MOM. Oshima
M. Oshima
RSR. G. Smith
R. G. Smith
DMD. Mosier
D. Mosier
MAM. Z. Atassi
M. Z. Atassi

1 April 2015 in Infection and Immunity
Verified
Journal Article
Closed access
BABalasubramanium Ayyar
Balasubramanium Ayyar
KAK. Roger Aoki
K. Roger Aoki
MAM. Zouhair Atassi
M. Zouhair Atassi
Botulinum neurotoxins (BoNTs) possess unique specificity for nerve terminals. They bind to the presynaptic membrane and then translocate intracellularly, where the light-chain endopeptidase cleaves the SNARE complex proteins, subverting the synaptic exocytosis responsible for acetylcholine release to the synaptic cleft. This inhibits acetylcholine binding to its receptor, causing paralysis. Binding, an obligate event for cell intoxication, is believed to occur through the heavy-chain C-terminal (H C ) domain. It is followed by toxin translocation and entry into the cell cytoplasm, which is thought to be mediated by the heavy-chain N-terminal (H N ) domain. Submolecular mapping analysis by using synthetic peptides spanning BoNT serotype A (BoNT/A) and mouse brain synaptosomes (SNPs) and protective antibodies against toxin from mice and cervical dystonia patients undergoing BoNT/A treatment revealed that not only regions of the H C domain but also regions of the H N domain are involved in the toxin binding process. Based on these findings, we expressed a peptide corresponding to the BoNT/A region comprising H N domain residues 729 to 845 (H N 729–845). H N 729–845 bound directly to mouse brain SNPs and substantially inhibited BoNT/A binding to SNPs. The binding involved gangliosides GT1b and GD1a and a few membrane lipids. The peptide bound to human or mouse neuroblastoma cells within 1 min. Peptide H N 729–845 protected mice completely against a lethal BoNT/A dose (1.05 times the 100% lethal dose). This protective activity was obtained at a dose comparable to that of the peptide from positions 967 to 1296 in the H C domain. These findings strongly indicate that H N 729–845 and, by extension, the H N domain are fully programmed and equipped to bind to neuronal cells and in the free state can even inhibit the binding of the toxin.

1 January 2012 in Immunobiology
Verified
Journal Article
Closed access
MAM. Zouhair Atassi
M. Zouhair Atassi
JJJoseph Jankovic
Joseph Jankovic
LSLance E. Steward
Lance E. Steward
KAK. Roger Aoki
K. Roger Aoki
BDBehzod Z. Dolimbek
Behzod Z. Dolimbek

28 October 2015 in Scientific Reports
Verified
Journal Article
Open access
BABalasubramanium Ayyar
Balasubramanium Ayyar
RTRajeev Tajhya
Rajeev Tajhya
CBChristine Beeton
Christine Beeton
MAM. Zouhair Atassi
M. Zouhair Atassi
Botulinum neurotoxins (BoNTs) are the most toxic substances known. BoNT intoxicates cells in a highly programmed fashion initiated by binding to the cell surface, internalization and enzymatic cleavage of substrate, thus, inhibiting synaptic exocytosis. Over the past two decades, immunological significance of BoNT/A C-terminal heavy chain (HC) and light chain (LC) domains were investigated extensively leading to important findings. In the current work, we explored the significance of BoNT/A heavy chain N-terminal (HN) region as a vaccine candidate. Mice were immunized with recombinant HN519–845 generating antibodies (Abs) that were found to be protective against lethal dose of BoNT/A. Immuno-dominant regions of HN519–845 were identified and individually investigated for antibody response along with synthetic peptides within those regions, using in vivo protection assays against BoNT/A. Results were confirmed by patch-clamp analysis where anti-HN antibodies were studied for the ability to block toxin-induced channel formation. This data strongly indicated that HN519–593 is an important region in generating protective antibodies and should be valuable in a vaccine design. These results are the first to describe and dissect the protective activity of the BoNT/A HN domain.

1 January 2007 in Critical Reviews in Immunology
Verified
Journal Article
Closed access
MAM. Zouhair Atassi
M. Zouhair Atassi
BDBehzod Z. Dolimbek
Behzod Z. Dolimbek
LSLance E. Steward
Lance E. Steward
KAK. Roger Aoki
K. Roger Aoki
In studies from this laboratory, we localized the regions on the H chain of botulinum neurotoxin A (BoNT/A) that are recognized by anti-BoNT/A antibodies (Abs) and block the activity of the toxin in vivo. These Abs were obtained from cervical dystonia patients who had been treated with BoNT/A and had become unresponsive to the treatment, as well as blocking Abs raised in mouse, horse, and chicken. We also localized the regions involved in BoNT/A binding to mouse brain synaptosomes (snp). Comparison of spatial proximities in the three-dimensional structure of the Ab-binding regions and the snp binding showed that except for one, the Ab-binding regions either coincide or overlap with the snp regions. It should be folly expected that protective Abs when bound to the toxin at sites that coincide or overlap with snp binding would prevent the toxin from binding to nerve synapse and therefore block toxin entry into the neuron. Thus, analysis of the locations of the Ab-binding and the snp-binding regions provides a molecular rationale for the ability of protecting Abs to block BoNT/A action in vivo.